Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients.

Rohner E, Grabik M, Tonia T, Jüni P, Pétavy F, Pignatti F, Bohlius J.

PLoS One. 2017 Dec 11;12(12):e0189309. doi: 10.1371/journal.pone.0189309. eCollection 2017. Review.

2.

Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production.

Nakamura M, Zhang Y, Yang Y, Sonmez C, Zheng W, Huang G, Seki T, Iwamoto H, Ding B, Yin L, Foukakis T, Hatschek T, Li X, Hosaka K, Li J, Yu G, Wang X, Liu Y, Cao Y.

Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9635-E9644. doi: 10.1073/pnas.1703431114. Epub 2017 Oct 23.

PMID:
29078273
3.

Optimal hematocrit in an artificial microvascular network.

Piety NZ, Reinhart WH, Stutz J, Shevkoplyas SS.

Transfusion. 2017 Sep;57(9):2257-2266. doi: 10.1111/trf.14213. Epub 2017 Jul 5.

PMID:
28681482
4.

Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome.

Bian J, Chen B, Hershman DL, Marks N, Norris L, Schulz R, Bennett CL.

J Clin Oncol. 2017 Jun 10;35(17):1945-1951. doi: 10.1200/JCO.2017.72.6273. Epub 2017 Apr 25.

PMID:
28441110
5.

Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.

Mafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M, Maisano R.

Support Care Cancer. 2017 Sep;25(9):2779-2786. doi: 10.1007/s00520-017-3690-z. Epub 2017 Apr 9.

6.

Imatinib and spironolactone suppress hepcidin expression.

Mleczko-Sanecka K, da Silva AR, Call D, Neves J, Schmeer N, Damm G, Seehofer D, Muckenthaler MU.

Haematologica. 2017 Jul;102(7):1173-1184. doi: 10.3324/haematol.2016.162917. Epub 2017 Apr 6.

7.

Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.

Trotta F, Belleudi V, Fusco D, Amato L, Mecozzi A, Mayer F, Sansone M, Davoli M, Addis A.

BMJ Open. 2017 Mar 10;7(3):e011637. doi: 10.1136/bmjopen-2016-011637.

8.

S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of Inflammation by Inhibiting IL-6/STAT3 Pathway.

Wang M, Tang W, Xin H, Zhu YZ.

PLoS One. 2016 Sep 20;11(9):e0163289. doi: 10.1371/journal.pone.0163289. eCollection 2016.

9.

Is there any role of intravenous iron for the treatment of anemia in cancer?

Gemici C, Yetmen O, Yaprak G, Ozden S, Tepetam H, Ozyurt H, Mayadagli A.

BMC Cancer. 2016 Aug 20;16(1):661. doi: 10.1186/s12885-016-2686-2.

10.

Long-term cancer-related fatigue outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with hormonal therapy.

Luo HC, Lei Y, Cheng HH, Fu ZC, Liao SG, Feng J, Yin Q, Chen QH, Lin GS, Zhu JF, Xu JF, Wang D.

Medicine (Baltimore). 2016 Jun;95(25):e3948. doi: 10.1097/MD.0000000000003948.

11.

HOXB7 as a promising molecular marker for metastasis in cancers: a meta-analysis.

Liu FT, Ou YX, Zhang GP, Qiu C, Luo HL, Zhu PQ.

Onco Targets Ther. 2016 May 6;9:2693-9. doi: 10.2147/OTT.S104000. eCollection 2016.

12.

A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.

Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M.

Pharmacotherapy. 2016 Apr;36(4):402-14. doi: 10.1002/phar.1729. Epub 2016 Apr 1.

13.

Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial.

Miskulin DC, Majchrzak K, Tighiouart H, Muther RS, Kapoian T, Johnson DS, Weiner DE.

J Am Soc Nephrol. 2016 Jun;27(6):1801-10. doi: 10.1681/ASN.2015040468. Epub 2015 Dec 17.

14.

Target Hemoglobin May Be Achieved with Intravenous Iron Alone in Anemic Patients with Cardiorenal Syndrome: An Observational Study.

Ben-Assa E, Shacham Y, Shashar M, Leshem-Rubinow E, Gal-Oz A, Schwartz IF, Schwartz D, Silverberg DS, Chernin G.

Cardiorenal Med. 2015 Oct;5(4):246-53. doi: 10.1159/000433564. Epub 2015 Jul 4.

15.

KIAA0101 is associated with human renal cell carcinoma proliferation and migration induced by erythropoietin.

Fan S, Li X, Tie L, Pan Y, Li X.

Oncotarget. 2016 Mar 22;7(12):13520-37. doi: 10.18632/oncotarget.5876.

16.

Expression of platelet-derived growth factor BB, erythropoietin and erythropoietin receptor in canine and feline osteosarcoma.

Meyer FR, Steinborn R, Grausgruber H, Wolfesberger B, Walter I.

Vet J. 2015 Oct;206(1):67-74. doi: 10.1016/j.tvjl.2015.06.003. Epub 2015 Jun 6.

17.

Multicentre randomized controlled trial comparing ferric(III)carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients.

Borstlap WAA, Buskens CJ, Tytgat KMAJ, Tuynman JB, Consten ECJ, Tolboom RC, Heuff G, van Geloven N, van Wagensveld BA, C A Wientjes CA, Gerhards MF, de Castro SMM, Jansen J, van der Ven AWH, van der Zaag E, Omloo JM, van Westreenen HL, Winter DC, Kennelly RP, Dijkgraaf MGW, Tanis PJ, Bemelman WA.

BMC Surg. 2015 Jun 28;15:78. doi: 10.1186/s12893-015-0065-6. Erratum in: BMC Surg. 2015;15:110. van Geloven, N [corrected to van Geloven, A A W].

18.

Erythropoietin improves the accumulation and therapeutic effects of carboplatin by enhancing tumor vascularization and perfusion.

Doleschel D, Rix A, Arns S, Palmowski K, Gremse F, Merkle R, Salopiata F, Klingmüller U, Jarsch M, Kiessling F, Lederle W.

Theranostics. 2015 May 1;5(8):905-18. doi: 10.7150/thno.11304. eCollection 2015.

19.

Significant prognostic impact of chemoradiotherapy-induced hemoglobin decrease on treatment outcomes of nasopharyngeal carcinoma.

Liang XX, Li Q, Su Z, Lan XW, Ouyang PY, Mao YP, Shi DB, Deng WG, Cheng ZB, Wang SY, Xie FY.

J Cancer. 2015 Apr 2;6(6):502-10. doi: 10.7150/jca.11403. eCollection 2015.

20.

Epoetin beta for the treatment of chemotherapy-induced anemia: an update.

Galli L, Ricci C, Egan CG.

Onco Targets Ther. 2015 Mar 5;8:583-91. doi: 10.2147/OTT.S77497. eCollection 2015. Review.

Supplemental Content

Support Center